BNIP3: A Potential Drug Target for Neurological Disorders (G664)

Target Name: BNIP3

NCBI ID: G664

BNIP3: A Potential Drug Target for Neurological Disorders

BNIP3 (Brain-derived neurotrophic factor-induced protein 3) is a protein that is expressed in various tissues of the brain, including the neuron, and is considered a potential drug target for various neurological and psychiatric disorders. The protein is derived from the brain and has been shown to play a role in the development and progression of a number of neurological disorders, including Alzheimer's disease, Parkinson's disease, and depression.

BNIP3 has been shown to interact with several other proteins, including TrkB, a protein that is involved in the neurotransmitter circuitry of dopamine. This interaction between BNIP3 and TrkB has been shown to play a role in the regulation of neuronal excitability and the development of neurological disorders.

In addition to its role in the nervous system, BNIP3 has also been shown to play a role in cancer. Studies have shown that BNIP3 can promote the growth and survival of cancer cells, making it a potential target for cancer treatment.

Despite the potential for BNIP3 as a drug target, much research is still needed to fully understand its role in the nervous system and cancer. In addition, the use of BNIP3 as a drug target may also have ethical implications, as it may be used to treat individuals with psychiatric or neurological disorders who have a history of substance abuse or who are at risk for suicide.

Overall, BNIP3 is a protein that has the potential to be a drug target for a variety of neurological and psychiatric disorders. Further research is needed to fully understand its role in these conditions and to develop safe and effective treatments.

Protein Name: BCL2 Interacting Protein 3

Functions: Apoptosis-inducing protein that can overcome BCL2 suppression. May play a role in repartitioning calcium between the two major intracellular calcium stores in association with BCL2. Involved in mitochondrial quality control via its interaction with SPATA18/MIEAP: in response to mitochondrial damage, participates in mitochondrial protein catabolic process (also named MALM) leading to the degradation of damaged proteins inside mitochondria. The physical interaction of SPATA18/MIEAP, BNIP3 and BNIP3L/NIX at the mitochondrial outer membrane regulates the opening of a pore in the mitochondrial double membrane in order to mediate the translocation of lysosomal proteins from the cytoplasm to the mitochondrial matrix. Plays an important role in the calprotectin (S100A8/A9)-induced cell death pathway

More Common Targets